Ginkgo Bioworks Holdings, Inc.

ISIN US37611X2099

 | 

WKN A40KL9

Market cap (in EUR)
478 m
Country
United States
Sector
Healthcare
 

Overview

Description

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through the company's two core offerings, Canopy and Horizon. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
Show more Show less
Healthcare Healthcare Services Miscellaneous Healthcare United States

Financials

Key metrics

Market capitalisation, EUR 478 m
EPS, EUR -5.64
P/B ratio 0.9
P/E ratio -
Dividend yield -

Income statement (2024)

Revenue, EUR 210 m
Net income, EUR -506 m
Profit margin -240.94%

What ETF is Ginkgo Bioworks Holdings, Inc. in?

There is 1 ETF which contains Ginkgo Bioworks Holdings, Inc..
ETF Weight Investment focus Fund size (in m EUR)
L&G Artificial Intelligence UCITS ETF 1.82%
Equity
World
Technology
Social/Environmental
Artificial Intelligence
1,173
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.